Oscar Health, Inc. (NYSE:OSCR – Get Free Report) insider Adam Mcananey sold 9,092 shares of the business’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $31.45, for a total value of $285,943.40. Following the transaction, the insider owned 209,004 shares in the company, valued at approximately $6,573,175.80. This represents a 4.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Oscar Health Stock Up 2.0%
Shares of OSCR stock traded up $0.65 during trading hours on Tuesday, reaching $32.90. The company had a trading volume of 4,754,751 shares, compared to its average volume of 7,062,275. The company has a market capitalization of $10.15 billion, a P/E ratio of 23.50, a price-to-earnings-growth ratio of 0.66 and a beta of 2.37. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.09 and a current ratio of 1.09. Oscar Health, Inc. has a twelve month low of $10.69 and a twelve month high of $33.55. The stock’s fifty day simple moving average is $30.49 and its 200 day simple moving average is $22.87.
Oscar Health (NYSE:OSCR – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.10 EPS for the quarter, topping the consensus estimate of $0.40 by $0.70. Oscar Health had a return on equity of 38.45% and a net margin of 3.60%.The firm had revenue of $4.88 billion for the quarter, compared to analyst estimates of $4.73 billion. During the same period in the previous year, the company posted ($0.89) EPS. Oscar Health’s revenue for the quarter was up 70.4% on a year-over-year basis. As a group, sell-side analysts expect that Oscar Health, Inc. will post 1.54 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Oscar Health
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $30.00 price target on shares of Oscar Health in a research note on Tuesday, August 11th. Wall Street Zen upgraded Oscar Health from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 14th. Wells Fargo & Company lifted their target price on Oscar Health from $20.00 to $27.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 13th. Barclays boosted their price target on Oscar Health from $35.00 to $39.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Finally, Robert W. Baird set a $27.00 price objective on Oscar Health in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $26.22.
View Our Latest Stock Report on OSCR
Oscar Health Company Profile
Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.
The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.
Featured Stories
- Five stocks we like better than Oscar Health
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for Oscar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oscar Health and related companies with MarketBeat.com's FREE daily email newsletter.
